Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

Nature Medicine

Volumn 23, Issue , 2017, Pages 579-589

  West, Nathaniel R ^a,b   Hegazy, Ahmed N ^a,b   Owens, Benjamin M J ^c   Bullers, Samuel J ^a   Linggi, Bryan ^d   Buonocore, Sofia ^e   Coccia, Margherita ^e   Görtz, Dieter ^f   This, Sébastien ^b   Stockenhuber, Krista ^a,b   Pott, Johanna ^e   Friedrich, Matthias ^a   Ryzhakov, Grigory ^a   Baribaud, Frédéric ^d   Brodmerkel, Carrie ^d   Cieluch, Constanze ^g   Rahman, Nahid ^h   Müller Newen, Gerhard ^f   Owens, Raymond J ^h,i   Kühl, Anja A ^g   Maloy, Kevin J ^e   Plevy, Scott E ^d   Keshav, Satish ^b   Travis, Simon P L ^b   Powrie, Fiona ^a,b   Bailey, Adam ^b   Barnes, Ellie ^b   Bird Lieberman, Beth ^b   Brain, Oliver ^b   Braden, Barbara ^b   Collier, Jane ^j   East, James ^b   Howarth, Lucy ^j,k   Klenerman, Paul ^b   Leedham, Simon ^b   Palmer, Rebecca ^k   Rodrigues, Astor ^j,k   Simmons, Alison ^b   Sullivan, Peter ^j,k   Uhlig, Holm ^b   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SOMERVILLE COLLEGE   (United Kingdom)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f RWTH AACHEN UNIVERSITY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h RUTHERFORD APPLETON LABORATORY   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; ONCOSTATIN M; ONCOSTATIN M RECEPTOR; TUMOR NECROSIS FACTOR; CHEMOKINE; GASTROINTESTINAL AGENT; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOSTATIN M RECEPTOR BETA; OSM PROTEIN, HUMAN; OSM PROTEIN, MOUSE; OSMR PROTEIN, HUMAN; OSMR PROTEIN, MOUSE;

ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; ENTERITIS; GENE DELETION; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINAL STEM CELL; INTESTINE TISSUE; LEUKOCYTE ADHERENCE; MAJOR CLINICAL STUDY; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; T LYMPHOCYTE; TREATMENT FAILURE; ULCERATIVE COLITIS; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; COLITIS; DISEASE MODEL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; KNOCKOUT MOUSE; MALE; METABOLISM; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CHEMOKINES; COLITIS; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL AGENTS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA SUBUNIT; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85016977937     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4307     Document Type: Article

References (66)

1. Uniken Venema, W.T., Voskuil, M.D., Dijkstra, G., Weersma, R.K. & Festen, E.A. The genetic background of inflammatory bowel disease: from correlation to causality. J. Pathol. 241, 146–158 (2017).
2. Basson, A., Trotter, A., Rodriguez-Palacios, A. & Cominelli, F. Mucosal interactions between genetics, diet, and microbiome in inflammatory bowel disease. Front. Immunol. 7, 290 (2016).
3. de Souza, H.S.P. & Fiocchi, C. Immunopathogenesis of IBD: current state of the art. Nat. Rev. Gastroenterol. Hepatol. 13, 13–27 (2016).
4. Maloy, K.J. & Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298–306 (2011).
5. Neurath, M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14, 329–342 (2014).
6. Chen, M.L. & Sundrud, M.S. Cytokine networks and T-cell subsets in inflammatory bowel diseases. Inflamm. Bowel Dis. 22, 1157–1167 (2016).
7. Ben-Horin, S. & Chowers, Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat. Rev. Gastroenterol. Hepatol. 11, 243–255 (2014).
8. Guerra, I. & Bermejo, F. Management of inflammatory bowel disease in poor responders to infliximab. Clin. Exp. Gastroenterol. 7, 359–367 (2014).
9. Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).
10. Garbers, C. et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 23, 85–97 (2012).
11. Richards, C.D. The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm. 2013, 512103 (2013).
12. Hermanns, H.M. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 26, 545–558 (2015).
13. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
14. Beigel, F. et al. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. PLoS One 9, e93498 (2014).
15. Sanchez, A.L. et al. Adenoviral transfer of the murine oncostatin M gene suppresses dextran-sodium sulfate-induced colitis. J. Interferon Cytokine Res. 23, 193–201 (2003).
16. Haberman, Y. et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J. Clin. Invest. 124, 3617–3633 (2014).
17. Vanhove, W. et al. Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease. Inflamm. Bowel Dis. 21, 2673–2682 (2015).
18. Arijs, I. et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 4, e7984 (2009).
19. Galamb, O. et al. Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br. J. Cancer 102, 765–773 (2010).
20. Planell, N. et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut 62, 967–976 (2013).
21. D’Haens, G.R. et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn′s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am. J. Gastroenterol. 106, 199–212 (2011).
22. Arijs, I. et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58, 1612–1619 (2009).
23. Toedter, G. et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. Am. J. Gastroenterol. 106, 1272–1280 (2011).
24. Sandborn, W.J. et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137, 1250–1260 (2009).
25. Sandborn, W.J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146, 85–95 (2014).
26. Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091–1093 (2009).
27. + Stromal cells are non-professional innate immune effectors of the human colonic mucosa. Front. Immunol. 4, 307 (2013).
28. Owens, B.M.J. Inflammation, innate immunity, and the intestinal stromal cell niche: opportunities and challenges. Front. Immunol. 6, 319 (2015).
29. Vicente-Suarez, I. et al. Unique lamina propria stromal cells imprint the functional phenotype of mucosal dendritic cells. Mucosal Immunol. 8, 141–151 (2015).
30. Peduto, L. et al. Inflammation recapitulates the ontogeny of lymphoid stromal cells. J. Immunol. 182, 5789–5799 (2009).
31. Baptista, A.P. et al. Colonic patch and colonic SILT development are independent and differentially regulated events. Mucosal Immunol. 6, 511–521 (2013).
32. Astarita, J.L., Acton, S.E. & Turley, S.J. Podoplanin: emerging functions in development, the immune system, and cancer. Front. Immunol. 3, 283 (2012).
33. Fletcher, A.L., Acton, S.E. & Knoblich, K. Lymph node fibroblastic reticular cells in health and disease. Nat. Rev. Immunol. 15, 350–361 (2015).
34. Kullberg, M.C. et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203, 2485–2494 (2006).
35. Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564–568 (2014).
36. Kullberg, M.C. et al. Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. Infect. Immun. 69, 4232–4241 (2001).
37. + monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23. Mucosal Immunol. 9, 352–363 (2016).
38. Brolund, L., Küster, A., Korr, S., Vogt, M. & Müller-Newen, G. A receptor fusion protein for the inhibition of murine oncostatin M. BMC Biotechnol. 11, 3 (2011).
39. Feagan, B.G. et al. Ustekinumab as induction and maintenance therapy for Crohn’s Disease. N. Engl. J. Med. 375, 1946–1960 (2016).
40. Ryan, R.E. et al. Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis. Cytokine 72, 71–85 (2015).
41. Bottini, N. & Firestein, G.S. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat. Rev. Rheumatol. 9, 24–33 (2013).
42. McLean, L.P. & Cross, R.K. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev. Gastroenterol. Hepatol. 8, 223–240 (2014).
43. Murdaca, G. et al. Infection risk associated with anti-TNF-α agents: a review. Expert Opin. Drug Saf. 14, 571–582 (2015).
44. Komori, T., Tanaka, M., Senba, E., Miyajima, A. & Morikawa, Y. Deficiency of oncostatin M receptor β (OSMRβ) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice. J. Biol. Chem. 289, 13821–13837 (2014).
45. Hamada, T. et al. Oncostatin M gene therapy attenuates liver damage induced by dimethylnitrosamine in rats. Am. J. Pathol. 171, 872–881 (2007).
46. Nakamura, K., Nonaka, H., Saito, H., Tanaka, M. & Miyajima, A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39, 635–644 (2004).
47. Kubin, T. et al. Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell 9, 420–432 (2011).
48. Pöling, J. et al. Therapeutic targeting of the oncostatin M receptor-β prevents inflammatory heart failure. Basic Res. Cardiol. 109, 396 (2014).
49. Choy, E.H. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Arthritis Res. Ther. 15, R132 (2013).
50. Tanaka, M. & Hirabayashi, Y. Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 102, 3154–3162 (2003).
51. Morikawa, Y. et al. Essential function of oncostatin m in nociceptive neurons of dorsal root ganglia. J. Neurosci. 24, 1941–1947 (2004).
52. Pohin, M. et al. Oncostatin M overexpression induces skin inflammation but is not required in the mouse model of imiquimod-induced psoriasis-like inflammation. Eur. J. Immunol. 46, 1737–1751 (2016).
53. Guilloteau, K. et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J. Immunol. 184, 5263–5270 (2010).
54. Gazel, A. et al. A characteristic subset of psoriasis-associated genes is induced by oncostatin-M in reconstituted epidermis. J. Invest. Dermatol. 126, 2647–2657 (2006).
55. Boniface, K. et al. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J. Immunol. 178, 4615–4622 (2007).
56. Langdon, C. et al. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am. J. Pathol. 157, 1187–1196 (2000).
57. Hui, W., Cawston, T.E., Richards, C.D. & Rowan, A.D. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL. Arthritis Res. Ther. 7, R57–R64 (2005).
58. Hui, W., Rowan, A.D., Richards, C.D. & Cawston, T.E. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum. 48, 3404–3418 (2003).
59. Hintzen, C., Quaiser, S., Pap, T., Heinrich, P.C. & Hermanns, H.M. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthritis Rheum. 60, 1932–1943 (2009).
60. Ott, C. & Schölmerich, J. Extraintestinal manifestations and complications in IBD. Nat. Rev. Gastroenterol. Hepatol. 10, 585–595 (2013).
61. Geremia, A. et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127–1133 (2011).
62. Becker, C., Fantini, M.C. & Neurath, M.F. High resolution colonoscopy in live mice. Nat. Protoc. 1, 2900–2904 (2007).
63. Izcue, A. et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28, 559–570 (2008).
64. + T cells during cure of colitis. J. Immunol. 177, 5852–5860 (2006).
65. West, N.R., Murray, J.I. & Watson, P.H. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 33, 1485–1494 (2014).
66. West, N.R., Murphy, L.C. & Watson, P.H. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer. Endocr. Relat. Cancer 19, 181–195 (2012).